* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Polypharmacy in Older Adults: Risks and Strategies To
Specialty drugs in the United States wikipedia , lookup
Orphan drug wikipedia , lookup
Neuropsychopharmacology wikipedia , lookup
Polysubstance dependence wikipedia , lookup
Pharmaceutical marketing wikipedia , lookup
Electronic prescribing wikipedia , lookup
Compounding wikipedia , lookup
Atypical antipsychotic wikipedia , lookup
Drug design wikipedia , lookup
Psychopharmacology wikipedia , lookup
Pharmacognosy wikipedia , lookup
Adherence (medicine) wikipedia , lookup
Neuropharmacology wikipedia , lookup
Theralizumab wikipedia , lookup
Drug discovery wikipedia , lookup
Pharmaceutical industry wikipedia , lookup
Pharmacokinetics wikipedia , lookup
Prescription costs wikipedia , lookup
Suboptimal Drug Use in Long Term Care Facility Patients Joseph T. Hanlon PharmD, MS Professor, Departments of Medicine (Geriatrics) and Pharmacy and Therapeutics, University of Pittsburgh and Pittsburgh VA CHERP and GRECC Learning Objectives At the end of the talk the participants should be able to: • List the different types of suboptimal drug use • Describe the prevalence of polypharmacy (9+ drugs) in long term care patients • Discuss the underuse of medications in long term care patients • Summarize drugs that are potentially inappropriate or unnecessary as per new CMS Guidelines for LTCF • Discuss principles to optimize drug use in long term care patients Types of Suboptimal Drug Use 1. Overutilization (polypharmacy) 2. Underutilization 3. Inappropriate utilization Hanlon JT, et al. J Am Geriatr Soc 2001;49:200-9; Spinewine A, et al. Lancet 2007;370:173-184 % Taking 9+ Meds in LTCFs 80 70 Percent of NHR 60 50 40 30 20 10 0 National VA CMS data, 1st quarter, 2005, VA NHCU data FY 04-05 Top Medication Classes Used in LTCF Medication Class 1997 MCBS % Analgesics/Anti-pyretics 76.5 GI agents 74.5 Electrolytes, caloric 71.0 CNS agents 65.9 Anti-infectives 62.3 Cardiovascular 55.0 Topical or other 47.1 Renal/GU Tract 44.4 Hormones/Synthetic subs 40.5 Respiratory agents 35.8 Anti-allergy agents 22.4 Blood formation/anti-coagulants 17.7 Doshi JA, et al. J Am Geriatr Soc. 2005;53:438-44. Top Medication Classes Used in VA NHCU FY 2005 (n=6554) VA Medication Class FY 05 % Non-opioid analgesics 73.3 SSRI Antidepressants 54.3 Anti-infectives Antipsychotics GI, misc. Stool Softeners 53.3 48.8 47.9 40.9 ACE-I 39.4 Beta blockers 39.3 Antiepileptics 38.0 MVI w/minerals 36.2 Stimulant Laxatives 34.6 Topical antifungals 34.4 Antilipemics 33.0 French DD, et al. J Am Med Dir 2007; 8:515-8 Daily Use of Specific Medication Classes in LTCF Patients per MDS Drug Class Diuretics Antidepressants Antipsychotics Antianxiety agents Hypnotics VA % 29.8 43.0 25.9 9.6 3.8 National % 34.0 48.4 24.9 12.8 3.7 CMS data, 2nd quarter, 2007, VA NHCU data FY 04-05 Risks Associated with Polypharmacy • • • • • Functional status decline ADRs Inappropriate drug use Increased medication administration errors Increased risk of geriatric syndromes Learning Objectives At the end of the talk the participants should be able to: • List the different types of suboptimal drug use • Describe the prevalence of polypharmacy (9+ drugs) in long term care patients • Discuss the underuse of medications in long term care patients • Summarize drugs that are potentially inappropriate or unnecessary as per new CMS Guidelines for LTCF • Discuss principles to optimize drug use in long term care patients Underutilization of Medication • Undiagnosed and untreated condition • Diagnosed condition but omitted treatment • Underuse of preventive treatment Examples of Medication Under-Use in LTCFs • Warfarin for stroke prevention (McCormick et al, 2001) • Hypoglycemics for diabetes (Spooner et al, 2000) • Calcium and other treatment for osteoporosis (Jachna et al, 2005) Inappropriate Prescribing • Prescribing of medications that does not agree with accepted medical standards MDS Quality Indicator Report Medication Use Antipsychotic Use w/o Psychosis Sxs of Depression w/o antidepressant Hypnotic use > 2x in previous week National % VA% 22.0 19.9 4.8 3.9 4.2 4.1 CMS Recommended Antianxiety and Sedative/Hypnotic Maximum Daily Dosage Generic Name Alprazolam Clonazepam Lorazepam Oxazepam Temazepam Zaleplon Zolpidem Dosage (mg) 0.75 7.5 1-2 15-30 7.5-15 5 5 Indications for Antipsychotics in the Elderly Nursing Home Patients 1. Disorders such as delirium, schizophrenia, paraphrenia, dementia With 2. Thinking and behavior disturbances such as delusions, hallucinations, paranoia And 3. Severe enough to be of harm to the patient and/or others Antipsychotic Guidelines in Nursing Home Elderly • Residents should receive gradual dose reductions, behavior interventions unless clinically contraindicated • Avoid use of highly anticholinergic antipsychotics (e.g., olanzapine, chlorpromazine, thioridazine, clozapine) • Specific doses recommended • Monitor for metabolic and EPS problems Weight Gain, Diabetes an Dyslipidemias with Atypical Antipsychotics Clozapine=Olanzapine>Quetiapine> Paliperidone=Risperidone>Ziprasidone=Aripiprazole ADA-APA Monitoring Guidelines Measure Baseline BMI x Waist Circ. x BP x FG x Lipids x 4wks x 8wks x 12wks x x x x 1/4ly Yrly x x x x CMS Recommended Selected Antipsychotic Maximum Daily Dosage Name Dosage (mg) Fluphenazine Haloperidol Perphenazine Quetiapine Risperidone 4 2 8 150 2 Inappropriate Medication Use Defined by Explicit Criteria (Beers MH, et al. 1997) • • • • • CARDIOVASCULAR Reserpine, Methyldopa, Disopyramide ANTIPLATELETS Dipyridamole, Ticlopidine DEMENTIA TREATMENTS GASTROINTESTINAL Antispasmodics (e.g., Donnatal®) Trimethobenzamide (Tigan®) ANALGESICS Indomethacin , Phenylbutazone Propoxyphene , Pentazocine, Meperidine • • • • • ORAL HYPOGLYCEMICS Chlorpropamide (Diabinese®) PSYCHOTROPICS Long acting benzodiazepines Meprobamate, Barbiturates Amitriptyline, Doxepin Antidepressant/neuroleptic Comb. SKELETAL MUSCLE RELAXANTS ANTIHISTAMINES Diphenhydramine (Benadryl® ) GU ANTISPASMODICS Oxybutynin Use of Beers Criteria Drugs in Nursing Homes J Am Geriatr Soc. 2005;53:991-6. Predictive Validity of Inappropriate Drug Use Author/yr Sample Criteria Outcome Lau/2005 MEPS NH Beers (Do not use, dose, drug-dx interaction) Death (OR=1.28) Hospitalized (OR=1.27) Perri/2005 Georgia Medicaid NH Beers (do not use), duplication, drug-dx interaction Death/Hospitalized (OR=2.3) Klarin/2005 Swedish ALF/NH Beers (high severity do not use), DDI, duplication Death (OR=0.93) Hospitalized (OR=2.72) Ravio/2006 Finland NH Beers (do not use, dose) Death (HR=1.02) Hospitalized (OR= 1.40) Inappropriate Medication Use Defined by CMS Criteria 2006 • • • • ANTIINFECTIVE Nitrofurantoin CARDIOVASCULAR Amiodarone (unless VT/Fib), Disopyramide, Methyldopa, Nifedipine (SA), Prazosin ANTIPLATELETS Ticlopidine GASTROINTESTINAL Antispasmodics (e.g., Donnatal®), Cimetidine, Metoclopramide, Trimethobenzamide (Tigan®) • • • • • ANALGESICS NSAIDs, Propoxyphene , Pentazocine, long acting opioids (fentanyl patch, methadone, SR products) ORAL HYPOGLYCEMICS Chlorpropamide, Glyburide PSYCHOTROPICS Barbiturates, Meprobamate, TCA’s, MAOIs SKELETAL MUSCLE RELAXANTS ANTIHISTAMINES Chlorpheniramine, Cyproheptadine, Diphenhydramine, Hydroxyzine, Meclizine, Promethazine Unnecessary Medications • Defined as a medication with excessive dose or duration; inadequate monitoring or indication for use; presence of adverse consequences which indicate the dose should be reduced or d/ced CMS Recommended Maximum Daily Dosage Generic Name APAP Digoxin H2 blockers Iron Metformin Daily Dosage (mg) 4000 0.125 (unless Afib) based on renal function qd based on renal function CMS Guidelines For Drugs with Maximum Duration Limits Drug Class ACHEI Analgesics Anti-infectives Antiemetics Cough/Cold H2 blocker/PPI Iron Duration (days) ? Revaluate as dx progresses ? acute use ? ? 14 84 (unless GERD/NSAID use) 56 CMS Guidelines for Monitoring Medication Use Drug ACE-I AEDS (older) Aminoglycosides Antidiabetics Antipsychotics APAP (>4gm/d) Appetite stimulants Digoxin Diuretic Erythropoiesis stimulants Fibrates Iron Lithium Niacin Statins Theophylline Thyroid replacement Warfarin Monitoring K+ levels Scr, levels Blood sugar EPS, TD LFTS weight, appetite Scr, level K+ BP, iron, ferritin, CBC LFTS, CBC iron, ferritin, CBC level blood sugar, LFTs LFTs levels TFTs INR CMS Drug-Drug Interactions Drug Effected ASA ACE-I Anticholinergic Antihypertensives Antiplatelet CNS med Digoxin Lithium Meperidine Phenytoin Quinolones SSRI Sulfonylureas Theophylline Warfarin Precipitant Drug (s) NSAIDs K supplements, K sparing diuretics Anticholinergic levodopa, nitrates NSAID CNS med amiodarone, verapamil ACEI, thiazide diuretics, NSAIDs MAOI imidazoles Type IA,C, II antiarrhythmics tramadol, st john wort imidazoles imidazoles, quinolones, barbiturates amiodarone, NSAIDs, sulfonamides, macrolides, quinolones, phenytoin, imidazoles Clinically Important Drug-Disease Interactions Determined by Expert Panel Consensus Drug Disease – Alpha blockers – Anticholinergics – – – – – – – Aspirin Barbiturates Benzodiazepines Bupropion CCB 1st generation Corticosteroids Digoxin Syncope BPH, constipation, dementia, glaucoma (narrow angle) PUD Dementia Dementia, falls Seizures CHF (systolic dysfunction) DM Heart block Lindblad C, Hanlon J et al. Clin Ther 2006;28:1133-43. Clinically Important Drug-Disease Interactions Determined by Expert Panel Consensus Drug – – – – – – Metoclopramide Non-aspirin NSAIDs Opioid analgesics Sedative/hypnotics Thioridazine Tricyclic antidepressants – Typical antipsychotics Disease Parkinson’s disease CRF, PUD Constipation Falls Postural hypotension BPH, constipation dementia, falls, heart block postural hypotension Falls Lindblad C, Hanlon J et al. Clin Ther 2006;28:1133-43. Medications with Anticholinergic Activity • • • • • • Anti-emetics/anti-vertigo - (e.g., meclizine) Antiparkinsonians - (e.g., trihexyphenidyl) Antispasmodics- (e.g., belladonna) Cold and allergy drugs- (e.g., hydroxyzine) Sleep aids- (e.g., diphenhydramine) Skeletal muscle relaxants - (e.g., cyclobenzaprine) Atypical Antipsychotic Medications and Risk of Falls in Residents of Aged Care Facilities Medication Olanzapine Risperidone Typ. antipsychotics Antidepressants Sed/anxiolytics Adj Hazard Ratio 1.74 1.32 1.35 1.45 1.19 95% CI (1.04–2.90) (0.57–3.06) (0.87–2.09) (1.09–1.93) (0.94–1.50) Hien LTT, et al. J Am Geriatr Soc 2006;53: 1290-1295. Antipsychotic Medications and Risk of Hip Fractures in NH Residents Medication Atypicals Olanzapine Risperidone Conv. antipsychotics Haloperidol Adj. OR 1.37 1.34 1.42 1.35 1.53 95% CI 1.11-1.69 0.87–2.07 1.12–1.80 1.06–1.71 1.18–2.26 Liperoti R, et al. J Clin Psych 2007;68: 929-34. Learning Objectives At the end of the talk the participants should be able to: • List the different types of suboptimal drug use • Describe the prevalence of polypharmacy (9+ drugs) in long term care patients • Discuss the underuse of medications in long term care patients • Summarize drugs that are potentially inappropriate or unnecessary as per new CMS Guidelines for LTCF • Discuss principles to optimize drug use in long term care patients Principles for Optimizing Drug Use in the Elderly • Consider whether drug therapy is necessary • Promote the use of a small number of drugs to treat common problems • Adjust doses and or/dosage intervals for medications • Establish reasonable therapeutic endpoints and monitor for desired outcome • Monitor for adverse drug reactions • Regularly review the need for chronic medications A Model for Appropriate Prescribing for Patients Late in Life Holmes HM, et al. Arch Intern Med 2006;166:605-609. Chronic Medication Review Steps • Assess whether ADRs are the cause of any symptoms • Match problem list with drug list • If on drug but no match with problem list consider whether drug is necessary • If has a chronic condition and not on a medication consider whether there is an evidence based drug to tx the condition • Assess the monitoring for efficacy/safety/appropriateness of the remaining medications Assessing Prescribing Appropriateness Using the MAI • • • • • • • • • • Is there an indication for the drug? Is the medication effective for the condition? Is the dosage correct? Are the directions correct? Are the directions practical? Are there clinically significant drug-drug interactions? Are there clinically significant drug-disease interactions? Is there unnecessary duplication with other drugs? Is the duration of therapy acceptable? Is this drug the least expensive alternative compared to others of equal utility? Effect of an Interdisciplinary Team on Suboptimal Prescribing in a VA LTCF (n=23) Variable Scheduled meds (mean ± sd) Unnecessary meds (mean ± sd) Inappropriate meds (Beers Criteria) % MAI Score/Person (mean ± sd) Undertreated conditions (mean ± sd) Admission Closeout 7.4 ± 2.8 7.3 ± 3.53 P Value 0.16 1.6 ± 1.5 0.3 ± 0.7 <0.001 17 0 ------- 16.7 + 10.6 7.9 + 5.1 <0.001 0.5 + 0.7 0.03 0.2 + 0.4 Jeffery S, et al. Consult Pharm 1999;14:1386-91. Learning Objectives At the end of the talk the participants should be able to: • List the different types of suboptimal drug use • Describe the prevalence of polypharmacy (9+ drugs) in long term care patients • Discuss the underuse of medications in long term care patients • Summarize drugs that are potentially inappropriate or unnecessary as per new CMS Guidelines for LTCF • Discuss principles to optimize drug use in long term care patients To Register for this Program and get CE Credit • Non-VA listeners go to: https://www.ees-learning.net • VA listeners go to: https://www.lms.va.gov/plateau/user/login.jsp 1) Log in. (If you have not done this before, contact your local LMS Administrator.) 2) On the upper right, where it says “Search Catalog” type in “GERIATRICS” and click on “GO” 3) Scroll down to “Suboptimal Drug Use in Long Term Care Facility Patients” 4) Click on “Link to Evaluation and Certificate” If listeners experience difficulty with the above, please contact the LMS Help Desk: 1-866-496-0463 or email: [email protected]